ScholarIQanswers from OpenAlex

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

PaperCitations, authors & open-access status

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma have?

ScholarIQcitation count

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma has 751 citations in the OpenAlex counts ScholarIQ stores.

When was Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma published?

ScholarIQyear

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma has 2006 year in the ScholarIQ index.

What is the open-access status of Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma?

ScholarIQoa status

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma has bronze oa status in the ScholarIQ index.

What is the DOI of Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma?

ScholarIQdoi

The DOI for Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma is on the source record.

What is the PMID of Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma?

ScholarIQpmid

The PMID for Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma is on the source record.

What is the OpenAlex record for Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma?

ScholarIQopenalex

The OpenAlex for Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial